Related references
Note: Only part of the references are listed.An association between the rs1799853 and rs1057910 polymorphisms of CYP2C9, the rs4244285 polymorphism of CYP2C19 and the prevalence rates of drug-resistant epilepsy in children
Marianna Makowska et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2021)
Possible Genetic Determinants of Response to Phenytoin in a Group of Colombian Patients With Epilepsy
Carlos Alberto Calderon-Ospina et al.
FRONTIERS IN PHARMACOLOGY (2020)
Effects of carbamazepine on the P-gp and CYP3A expression correlated with PXR or NF-κB activity in the bEnd.3 cells
Xian-jin Ke et al.
NEUROSCIENCE LETTERS (2019)
Overexpression of pregnane X and glucocorticoid receptors and the regulation of cytochrome P450 in human epileptic brain endothelial cells
Chaitali Ghosh et al.
EPILEPSIA (2017)
Use of multi-dose activated charcoal in phenytoin toxicity secondary to genetic polymorphism
Betty S. H. Chan et al.
CLINICAL TOXICOLOGY (2015)
CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects
Valentina Franco et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
Clinical relevance of genetic polymorphism in the CYP2C9 gene to pharmacodynamics and pharmacokinetics of phenytoin in epileptic patients: validatory pharmacogenomic approach to pharmacovigilance
Shazia Kousar et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2015)
Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children
Supharat Suvichapanich et al.
JOURNAL OF HUMAN GENETICS (2015)
Padaczka oporna na leczenie – epidemiologia i aktualny stan badań
Krystyna Pierzchała
Neurologia i Neurochirurgia Polska (2014)
CYP3A5*3 and C3435T MDR1 Polymorphisms in Prognostication of Drug-Resistant Epilepsy in Children and Adolescents
Ewa Emich-Widera et al.
BIOMED RESEARCH INTERNATIONAL (2013)
The genetic variability and commonality of neurodevelopmental disease
Bradley P. Coe et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS (2012)
Genetic variability and haplotype profile of MDR1 in Saudi Arabian males
Abdullah M. Al-Mohizea et al.
MOLECULAR BIOLOGY REPORTS (2012)
Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies
Patrick Kwan et al.
EPILEPSIA (2010)
Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment
Sandeep Grover et al.
PHARMACOGENOMICS (2010)
Non-response to antiepileptic pharmacotherapy is associated with the ABCC2-24C>T polymorphism in young and adult patients with epilepsy
Mike Ufer et al.
PHARMACOGENETICS AND GENOMICS (2009)
Prevalence of CYP2C9 polymorphisms in the south of Europe
Paula Sanchez-Diz et al.
PHARMACOGENOMICS JOURNAL (2009)
CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects
Y Soga et al.
LIFE SCIENCES (2004)
Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population
SI Hamdy et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population
MG Scordo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
The effect of genetic polymorphism of cytochrome P450CYP2C9 on phenytoin dose requirement
J van der Weide et al.
PHARMACOGENETICS (2001)
Share Paper
